Vertex Pharmaceuticals and Zai Lab have entered into an exclusive agreement to develop and commercialize povetacicept in mainland China, Hong Kong SAR, Macau SAR, Taiwan, and Singapore. Povetacicept, a dual antagonist targeting BAFF and APRIL cytokines, is being studied for B cell-mediated diseases, including IgA nephropathy. Under the partnership, Zai Lab will advance clinical trials, manage regulatory submissions, and oversee commercialization upon approval. Vertex will receive upfront payments, regulatory milestones, and tiered royalties. This collaboration aims to accelerate access to povetacicept for patients in the licensed regions. (Source: Vertex Pharmaceuticals)